Cocrystal Pharma Stock Analysis

Cocrystal Stock Analysis Notes

About 32.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.78. Some equities with similar Price to Book (P/B) outperform the market in the long run. Cocrystal Pharma has Price/Earnings (P/E) ratio of 193.33. The entity recorded a loss per share of 0.93. The firm last dividend was issued on the 24th of January 2018. Cocrystal Pharma had 1:12 split on the 11th of October 2022. Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious andor chronic viral diseases. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp Dohme Corp. to discover and develop proprietary influenza AB antiviral agents a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections and drug discovery collaboration with HitGen and InterX Inc. Cocrystal Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. For more info on Cocrystal Pharma please contact CPA CPA at 877 262 7123 or go to https://www.cocrystalpharma.com.

Cocrystal Pharma Investment Alerts

Cocrystal Largest EPS Surprises

View All Earnings Estimates

Cocrystal Stock Institutional Investors

Note, although Cocrystal Pharma's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cocrystal Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 13.51 M.

Cocrystal Profitablity

Management Efficiency

Cocrystal Pharma has return on total asset (ROA) of (0.4577) % which means that it has lost $0.4577 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9494) %, meaning that it created substantial loss on money invested by shareholders. Cocrystal Pharma's management efficiency ratios could be used to measure how well Cocrystal Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of 02/03/2026, Return On Tangible Assets is likely to drop to -1.57. In addition to that, Return On Capital Employed is likely to drop to -1.53. At this time, Cocrystal Pharma's Total Current Liabilities is relatively stable compared to the past year. As of 02/03/2026, Non Current Liabilities Other is likely to grow to about 366.4 K, while Liabilities And Stockholders Equity is likely to drop slightly above 14.7 M.

Technical Drivers

As of the 3rd of February, Cocrystal Pharma shows the risk adjusted performance of (0.05), and Mean Deviation of 2.61. Cocrystal Pharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Cocrystal Pharma Price Movement Analysis

Cocrystal Pharma Insider Trading Activities

Cocrystal Pharma Outstanding Bonds

Cocrystal Pharma Predictive Daily Indicators

Cocrystal Pharma Forecast Models

Cocrystal Pharma's time-series forecasting models are one of many Cocrystal Pharma's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cocrystal Pharma's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Cocrystal Pharma Bond Ratings

Cocrystal Pharma financial ratings play a critical role in determining how much Cocrystal Pharma have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Cocrystal Pharma's borrowing costs.

Cocrystal Pharma Debt to Cash Allocation

Cocrystal Pharma currently holds 1.81 M in liabilities with Debt to Equity (D/E) ratio of 0.01, which may suggest the company is not taking enough advantage from borrowing. Cocrystal Pharma has a current ratio of 17.97, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Cocrystal Pharma's use of debt, we should always consider it together with its cash and equity.

Cocrystal Pharma Total Assets Over Time

Cocrystal Pharma Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Cocrystal Pharma uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Cocrystal Pharma Debt Ratio

21.0

It seems most of the Cocrystal Pharma's assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Cocrystal Pharma's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Cocrystal Pharma, which in turn will lower the firm's financial flexibility.

Cocrystal Pharma Corporate Bonds Issued

Cocrystal Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cocrystal Pharma prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cocrystal shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cocrystal Pharma. By using and applying Cocrystal Stock analysis, traders can create a robust methodology for identifying Cocrystal entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cocrystal analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cocrystal analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cocrystal Pharma stock analysis indicators help investors evaluate how Cocrystal Pharma stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cocrystal Pharma shares will generate the highest return on investment. By understating and applying Cocrystal Pharma stock analysis, traders can identify Cocrystal Pharma position entry and exit signals to maximize returns.

When running Cocrystal Pharma's price analysis, check to measure Cocrystal Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cocrystal Pharma is operating at the current time. Most of Cocrystal Pharma's value examination focuses on studying past and present price action to predict the probability of Cocrystal Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cocrystal Pharma's price. Additionally, you may evaluate how the addition of Cocrystal Pharma to your portfolios can decrease your overall portfolio volatility.